Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)

NCT01896973 | Terminated DMC

• 1 other identifier: 01.CP.0.1
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 2

Brief Summary

The HistoSonics' Histotripsy BPH Device, the Vortx Rx, is a portable ultrasound therapy device. The purpose of this study is to assess and monitor the performance of the Vortx Rx for initial safety and efficacy for the treatment of Benign Prostatic Hyperplasia.

Conditions

Benign Prostatic Hyperplasia (BPH)

Keywords

Benign Prostatic Hyperplasia; BPH; LUTS; Vortx Rx; Histotripsy

Outcome Measures

Primary Outcomes (1)

• Safety of the Vortx Rx for treatment of symptomatic BPH

  * Record and report all adverse events. * Determine rate of occurrence of adverse events, serious adverse events and device-related adverse events as a measure of safety and as factors used to determine study success.

  1 Day, 1, 3 and 6 months

Secondary Outcomes (1)

• Initial prostate histotripsy treatment efficacy

  1, 3 and 6 months

Study Arms (1)

Vortx Rx - Histotripsy BPH Device

EXPERIMENTAL

The Vortx Rx is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.

Device: Vortx Rx - Histotripsy BPH Device

Interventions

Vortx Rx - Histotripsy BPH Device DEVICE

Non-invasive histotripsy treatment/therapy to be delivered by the surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the end of the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.

Also known as: HistoSonics Histotripsy BPH device, Vortx Rx

Vortx Rx - Histotripsy BPH Device

Eligibility Criteria

• Age: 50 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of BPH and eligible for endoscopic BPH surgery including TURP, PVP, electrovaporization.
• Prostate volumes 30 - 80 gm based on transrectal ultrasound
• Men ≥ 50 years of age
• IPSS symptom score ≥ 13 and IPSS bother score \> 2 (see Appendix B for IPSS questionnaire)
• Baseline peak flow rate Qmax ≤ 15 cc/s with voided volume at least 125 cc

You may not qualify if:

• History of prostate or bladder cancer, pelvic radiation, untreated bladder stones, urethral strictures/bladder neck contracture (BNC), renal insufficiency (i.e. creatinine \> 1.4)
• Neurogenic bladder, Parkinson's disease
• Prior treatment for urinary incontinence
• Micturition frequency AND urgency. Micturition frequency defined as \> 8 micturitions per 24 hours as assessed by a thorough subject history including the question: "On average, how many times do you void during a 24 hour period? // \< 4, 5-7, 8 or more." Urgency defined as an uncontrollable urge to void that occurs \> 3 per 24 hours as assessed through the subject history/question: "On average, how many times a day do you have an uncontrollable urgency to void? // 0, 1-2, 3 or more?"
• Intravesical prostate lobe protrusion \> 1 cm on TRUS. Note: this is distinct from lateral lobes protruding up to the bladder such as an intravesical protrusion without median lobe
• Active UTI (i.e. must have a screening urinalysis without signs of infection or a negative urine culture)
• PVR \> 250 at time of enrollment or catheter dependent bladder drainage
• History of chronic prostatitis within the last 5 years
• Not able to temporarily discontinue aspirin, Coumadin, Plavix and any other anticoagulant at least seven days prior to the time of treatment
• History of known bleeding disorders (e.g. von Willebrand disease \[VWD\]) and subjects determined to have a bleeding disorder by prothrombin time (PT) and partial thromboplastin time (PTT) tests.
• Prior BPH prostate procedures (e.g. TUMT, TUNA, water induced thermotherapy \[WIT\], TURP, PVP)
• Men with confirmed or suspected malignancy of the prostate based on a digital rectal exam (DRE), prostate biopsy or PSA \> 10 ng/mL. Men with free PSA \< 25% and PSA between 2.5 and 10 ng/mL may only be enrolled after a negative biopsy. If a prior prostate biopsy was performed within one year of enrollment and was negative for cancer, repeat biopsy is not required if in the investigator's judgment there is no clinical evidence to support biopsy reassessment. If a biopsy is required, the subject shall have a six-week waiting period between the biopsy and histotripsy treatment, if he is otherwise deemed eligible to participate in the study.
• Men interested in future fertility
• Declines or unable to provide informed consent
• Non-English-speaker

Sponsors & Collaborators

• HistoSonics, Inc.: lead

Study Sites (2)

Univerisity of Michigan

Ann Arbor, Michigan, 48109, United States

Location

ProMedica Parkway Surgery Center

Toledo, Ohio, 43606, United States

Location

MeSH Terms

Conditions

Prostatic Hyperplasia

Condition Hierarchy (Ancestors)

Prostatic Diseases; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Male Urogenital Diseases

Study Officials

• Timonthy Schuster, MD

  ProMedica Parkway Surgery Center

  PRINCIPAL INVESTIGATOR

• John Wei, MD

  University of Michigan

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 8, 2013
• First Posted: July 11, 2013
• Study Start: July 1, 2013
• Primary Completion: December 1, 2016
• Study Completion: December 1, 2016
• Last Updated: November 7, 2023

Record last verified: 2023-11

Locations

US (2)